Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04438005 | A Study of ICP-022 in Patients With R/R DLBCL(DLBCL) | completed | Phase 2 | 3 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | May 13, 2024 | clinicaltrials |
| NCT02586038 | STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS | completed | Phase 2 | 175 | Mario BoccadoroOTHER | 1 |
| May 8, 2024 |
| clinicaltrials |
| NCT02728102 | Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) | completed | Phase 2 | 203 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | May 7, 2024 | clinicaltrials |
| NCT01063907 | A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 95 | Kyowa Kirin Co., Ltd.INDUSTRY | 3 | Apr 25, 2024 | clinicaltrials |
| NCT02445248 | Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients(JULIET) | completed | Phase 2 | 115 | Novartis PharmaceuticalsINDUSTRY | 10 | Apr 18, 2024 | clinicaltrials |
| NCT03797456 | A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) | completed | Phase 2 | 111 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT02100423 | Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 35 | Paolo Caimi, MDOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT00799513 | Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma(RV-NHL-PI351) | completed | Phase 2 | 48 | IRCCS San RaffaeleOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03848845 | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 4) | completed | Phase 1 / Phase 2 | 41 | GlaxoSmithKlineINDUSTRY | 4 | Apr 9, 2024 | clinicaltrials |
| NCT03310619 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies(PLATFORM) | completed | Phase 1 / Phase 2 | 62 | CelgeneINDUSTRY | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04028115 | Bone Healing During Ninlaro Exposure(BONE) | completed | Phase 2 | 30 | Thomas LundOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT02812706 | Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients(Islands) | completed | Phase 1 / Phase 2 | 36 | SanofiINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT02891811 | Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy | completed | Phase 2 | 124 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 2 | Mar 29, 2024 | clinicaltrials |
| NCT03450057 | Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment(DARE) | completed | Phase 2 | 38 | Hellenic Society of HematologyOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT04508647 | Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma | completed | Phase 2 | 4 | University of Colorado, DenverOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02420912 | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02119468 | Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT02636322 | Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT02926833 | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)(ZUMA-6) | completed | Phase 1 / Phase 2 | 37 | Kite, A Gilead CompanyINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT00019097 | Vaccine Therapy in Treating Patients With Multiple Myeloma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02056756 | Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Stichting European Myeloma NetworkNETWORK | 2 | Feb 20, 2024 | clinicaltrials |
| NCT04478123 | Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer | completed | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT01190787 | Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone | completed | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03506360 | Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03399513 | Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma(R-CHOEP-brut) | completed | Phase 2 | 40 | University Hospital MuensterOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT00520767 | Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease | completed | Phase 2 | 35 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05028374 | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | completed | Phase 2 | 119 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT04682405 | Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) | completed | Phase 2 | 51 | Washington University School of MedicineOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT01913730 | Maintenance Therapy With Subcutaneous Bortezomib | completed | Phase 2 | 63 | European Myeloma Network B.V.NETWORK | 1 | Dec 13, 2023 | clinicaltrials |
| NCT01393756 | Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma(R2-CHOP2) | completed | Phase 2 | 80 | The Lymphoma Academic Research OrganisationOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02843074 | Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients | completed | Phase 2 | 53 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT01145209 | Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03255018 | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2023 | clinicaltrials |
| NCT02834364 | BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)(GMMG-BIRMA) | completed | Phase 2 | 12 | University of Heidelberg Medical CenterOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03224507 | Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma(MASTER) | completed | Phase 2 | 123 | University of Alabama at BirminghamOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2023 | clinicaltrials |
| NCT00321555 | LMB-2 to Treat Hairy Cell Leukemia | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00734149 | Bortezomib With Melphalan and Prednisone for Multiple Myeloma(MVP) | completed | Phase 2 | 45 | Duke UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02639559 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02206425 | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02547662 | Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia | completed | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT00777998 | Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma | completed | Phase 2 | 221 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT00571662 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 76 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT02399085 | Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL(L-MIND) | completed | Phase 2 | 81 | MorphoSys AGINDUSTRY | 10 | Oct 23, 2023 | clinicaltrials |
| NCT02869633 | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | completed | Phase 2 | 23 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT02308280 | Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients | completed | Phase 2 | 40 | Maisonneuve-Rosemont HospitalOTHER | 1 | Oct 19, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2024source: clinicaltrials